[{"id":"0f837c74-6645-47f4-8ca8-de1cded5acdd","acronym":"","url":"https://clinicaltrials.gov/study/NCT00911560","created_at":"2021-01-18T03:31:25.248Z","updated_at":"2024-07-02T16:34:38.224Z","phase":"Phase 1/2","brief_title":"Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma","source_id_and_acronym":"NCT00911560","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GD2-GD3 Vaccine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 374","initiation":"Initiation: 05/27/2009","start_date":" 05/27/2009","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-05"}]